相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Discovery of 1-Methyl-1H-imidazole Derivatives as Potent Jak2 Inhibitors
Qibin Su et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
James D. Clark et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis
Y. Nakaya et al.
BLOOD CANCER JOURNAL (2014)
Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis
Martin E. Dowty et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
3-O-methylthespesilactam, a new small-molecule anticancer pan-JAK inhibitor against A2058 human melanoma cells
Min-Yi Li et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1
Christopher A. Hurley et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors
Sharada Labadie et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors
Michael Siu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Lead identification of novel and selective TYK2 inhibitors
Jun Liang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
Inhibitors of JAK2 and JAK3: an update on the patent literature 2010-2012
Brian W. Dymock et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2013)
A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors
Sue J. Sohn et al.
JOURNAL OF IMMUNOLOGY (2013)
Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
Luc Van Rompaey et al.
JOURNAL OF IMMUNOLOGY (2013)
3-Amido Pyrrolopyrazine JAK Kinase Inhibitors: Development of a JAK3 vs JAK1 Selective Inhibitor and Evaluation in Cellular and in Vivo Models
Michael Soth et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2
Mark Zak et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Lead Optimization of a 4-Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors
Jun Liang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F
L. Ma et al.
BLOOD CANCER JOURNAL (2013)
TYK2-STAT1-BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia
Takaomi Sanda et al.
CANCER DISCOVERY (2013)
Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
Michaela Waibel et al.
CELL REPORTS (2013)
The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential
Maurizio Cutolo
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2013)
Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year
F. Vincenti et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases
Craig A. Zificsak et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors
Timothy Forsyth et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
J. Mascarenhas et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Selective JAK1 inhibitor and selective Tyk2 inhibitor patents
Peter Norman
EXPERT OPINION ON THERAPEUTIC PATENTS (2012)
Biology and significance of the JAK/STAT signalling pathways
Hiu Kiu et al.
GROWTH FACTORS (2012)
Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)
Anders Poulsen et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2012)
SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis
Babita Madan et al.
JOURNAL OF IMMUNOLOGY (2012)
Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,-4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis
Anthony D. William et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors
Emily J. Hanan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
A Selective, Orally Bioavailable 1,2,4-Triazolo[1;5-a]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779
Benjamin J. Dugan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors
Janusz J. Kulagowski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2
A. V. Purandare et al.
LEUKEMIA (2012)
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
Priya Koppikar et al.
NATURE (2012)
Tofacitinib safe and effective in renal transplant recipients
Helene Myrvang
Nature Reviews Nephrology (2012)
Phase III trial results for tofacitinib bring new oral DMARD therapy a step closer for patients with rheumatoid arthritis
Emma Leah
Nature Reviews Rheumatology (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib (CP-690,550), a Janus Kinase Inhibitor for Dry Eye Disease
Shiao Hui (Melissa) Liew et al.
OPHTHALMOLOGY (2012)
Development and a Practical Synthesis of the JAK2 Inhibitor LY2784544
David Mitchell et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2012)
Efficacious Intermittent Dosing of a Novel JAK2 Inhibitor in Mouse Models of Polycythemia Vera
Manfred Kraus et al.
PLOS ONE (2012)
TYK2 Kinase Activity Is Required for Functional Type I Interferon Responses In Vivo
Michaela Prchal-Murphy et al.
PLOS ONE (2012)
The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
V. Novotny-Diermayr et al.
BLOOD CANCER JOURNAL (2012)
Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
Rita Andraos et al.
CANCER DISCOVERY (2012)
Pyrrolo[1,2-f]triazines as JAK2 inhibitors: Achieving potency and selectivity for JAK2 over JAK3
Lalgudi S. Harikrishnan et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors
Tao Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: Modification of target structure to minimize reactive metabolite formation
Linda R. Weinberg et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm
Kotaro Shide et al.
BLOOD (2011)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis et al.
BLOOD (2011)
Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study
Jane E. Minturn et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
6-Bromoindirubin-3′-Oxime Inhibits JAK/STAT3 Signaling and Induces Apoptosis of Human Melanoma Cells
Lucy Liu et al.
CANCER RESEARCH (2011)
Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480
Hong Xin et al.
CANCER RESEARCH (2011)
Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors
Claude Haan et al.
CHEMISTRY & BIOLOGY (2011)
The Use of Structural Biology in Janus Kinase Targeted Drug Discovery
Nilda L. Alicea-Velazquez et al.
CURRENT DRUG TARGETS (2011)
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Animesh Pardanani et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Discovery of Potent and Highly Selective Thienopyridine Janus Kinase 2 Inhibitors
Laurie B. Schenkel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Identification of a Potent Janus Kinase 3 Inhibitor with High Selectivity within the Janus Kinase Family
Gebhard Thoma et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma
Anthony D. William et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Discovery of 5 Chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/Stat Pathway
Stephanos Ioannidis et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Discovery of 1-Amino-5H-pyrido[4,3-b]indol-4-carboxamide Inhibitors of Janus Kinase 2 (JAK2) for the Treatment of Myeloproliferative Disorders
Jongwon Lim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma
Braden C. McFarland et al.
MOLECULAR CANCER THERAPEUTICS (2011)
The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells
K. A. Monaghan et al.
LEUKEMIA (2011)
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
S. Hart et al.
LEUKEMIA (2011)
Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms
Y. Nakaya et al.
BLOOD CANCER JOURNAL (2011)
Selective Functional Inhibition of JAK-3 Is Sufficient for Efficacy in Collagen-Induced Arthritis in Mice
Tsung H. Lin et al.
ARTHRITIS AND RHEUMATISM (2010)
Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors
Carole Pissot-Soldermann et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors
Tiansheng Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
The discovery of tricyclic pyridone JAK2 inhibitors. Part 1: Hit to lead
Tony Siu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
Fabio P. S. Santos et al.
BLOOD (2010)
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
Jeffrey W. Tyner et al.
BLOOD (2010)
Recent developments on JAK2 inhibitors: a patent review
Robert Kiss et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2010)
Recent patents in the discovery of small molecule inhibitors of JAK3
Lawrence J. Wilson
EXPERT OPINION ON THERAPEUTIC PATENTS (2010)
Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
Jordan S. Fridman et al.
JOURNAL OF IMMUNOLOGY (2010)
Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection
Mark E. Flanagan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6
Jill E. Chrencik et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
Fabienne Baffert et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
Michael Hedvat et al.
CANCER CELL (2009)
TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients
T. L. Lasho et al.
LEUKEMIA (2008)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Orthogonal multipolar interactions in structural chemistry and biology
R Paulini et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2005)
High-throughput screening with quantitation of ATP consumption: A universal non-radioisotope, homogeneous assay for protein kinase
M Koresawa et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2004)
Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice
A Krempler et al.
GENESIS (2004)
A new modality for immunosuppression: Targeting the JAK/STAT pathway
JJ O'Shea et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
A comparison of physiochemical property profiles of development and marketed oral drugs
MC Wenlock et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
FLT3 and its role in the pathogenesis of acute myeloid leukaemia
JT Reilly
LEUKEMIA & LYMPHOMA (2003)
Is there a difference between leads and drugs? A historical perspective
TI Oprea et al.
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES (2001)
分享论文
